Clinical Trials Browser

Urinary Bladder Neoplasms × Rogaratinib × Clear all

NCT03473756 2025-04-09

FORT-2

Phase 1 Completed

37 enrolled 15 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Phase 1 Completed

168 enrolled 59 charts

GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04040725 2019-12-17

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Phase 2 Withdrawn

Urinary Bladder Neoplasms